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Cooperation between integrins and growth factor re-
ceptors plays an important role in the regulation of cell
growth, differentiation, and survival. The function of
growth factor receptor tyrosine kinases (RTKs) can be
regulated by cell adhesion to extracellular matrix (ECM)
even in the absence of ligand. We investigated the path-
way involved in integrin-mediated RTK activation, us-
ing RON, the receptor for macrophage-stimulating pro-
tein. Adhesion of RON-expressing epithelial cells to
ECM caused phosphorylation of RON, which depended
on the kinase activity of both RON itself and c-Src. This
conclusion is based on these observations: 1) ECM-in-
duced RON phosphorylation was inhibited in cells ex-
pressing kinase-inactive c-Src; 2) active c-Src could
phosphorylate immunoprecipitated RON from ECM-
stimulated cells but not from unstimulated cells; and 3)
ECM did not cause RON phosphorylation in cells ex-
pressing kinase-dead RON, nor could active c-Src phos-
phorylate RON immunoprecipitated from these cells.
The data fit a pathway in which ECM-induced integrin
aggregation causes both c-Src activation and RON oli-
gomerization followed by RON kinase-dependent auto-
phosphorylation; this results in RON becoming a target
for activated c-Src, which phosphorylates additional ty-
rosines on RON. Integrin-induced epidermal growth fac-
tor receptor (EGFR) phosphorylation also depended on
both EGFR and c-Src kinase activities. This sequence
appears to be a general pathway for integrin-dependent
growth factor RTK activation.
Growth, differentiation, and survival of anchorage-depend-
ent cells are regulated through signals generated by adhesion
to ECM1 and by soluble growth factors (1–5). Cell-matrix in-
teraction is mediated by integrins, transmembrane nonco-
valently linked heterodimeric receptors consisting of a and b
subunits (6). Integrin engagement by ECM can modulate
growth factor signaling pathways, increasing the activity of
growth factor RTKs (7, 8) and their downstream intracellular
mediators (9, 10). Integrin-based effects on growth factor re-
ceptors include enhancement of cell migration (11, 12), survival
(13), and proliferation (14–17).
As to the basis for their collaboration, integrins and growth
factor receptors may form macromolecular complexes on the
cell membrane (7, 8, 13, 16–18). In that case, adhesion-induced
aggregation of integrins might trigger co-aggregation (5) and
autophosphorylation of growth factor RTKs (13). Integrin-in-
duced epidermal growth factor (EGF) and platelet-derived
growth factor (PDGF) RTK phosphorylation depends on the
kinase activity of the receptor (7, 13). Recent data suggest that
integrin association with RTKs might also protect the latter
against the activity of phosphatases (17, 19) and/or ensure the
correct subcellular juxtaposition of cytoplasmic tails of dimer-
ized growth factor receptors (17). Despite the cited progress in
this area of research, the molecular mechanisms underlying
growth factor receptor activation by integrins remain to be
defined.
RON is an RTK that mediates the biological effects of mac-
rophage-stimulating protein (MSP) (20, 21). MSP was discov-
ered as a serum factor that regulates the motility of macro-
phages (22). Recent investigations have shown that the RON
receptor is expressed in various cell types including epithelial
cells (23) and that MSP-mediated effects on epithelial cells are
integrin-dependent (23, 24). In the present work, we investi-
gated the pathway involved in integrin-mediated activation of
RON.
EXPERIMENTAL PROCEDURES
Site-directed Mutagenesis of the RON Receptor—A kinase-dead
K1114M RON mutant was generated using the GeneEditor (Promega,
Madison, WI) mutagenesis kit with oligonucleotide GTGCCATCATGT-
CACTAAG.
Cells and Transfections—RE7 (20) (MDCK RON-expressing cells),
MDCK, and HEK 293 cells (ATCC, Manassas, VA) were grown in
DMEM with 10% FCS. HaCat cells (donated by Dr. N. Fusenig, Hei-
delberg, Germany) were grown in KSF medium with supplements.
For transient transfection of the HEK 293 cell line, cells were grown
to 70–80% confluence on 15-cm dishes and transfected with 20 mg of
RON cDNA or empty vector pCI-neo (Promega, Madison, WI) using
Superfect reagent (Qiagen, Santa Clarita, CA). For co-transfection, 10
mg of RON cDNA plus 10 mg of empty vector (MOCK), FAK Y397F, or
dominant-negative (dn) c-Src (K295M/Y527F) mutant DNAs were used.
For transient transfection of MDCK cells, 15 mg of empty vector or dn
c-Src were co-transfected together with 5 mg of MACS4 plasmid
(Miltenyi Biotec, Auburn, CA) using Superfect reagent. After 36 h,
successfully transfected cells were selected using a MACS4 selection kit
(Miltenyi Biotec).
Cell Stimulation, Lysis, Immunoprecipitation, and Western Blot-
ting—Cells were starved overnight in medium without serum and then
collected from dishes and stimulated with 5 nM MSP (Toyobo, Japan) or
50 mg/ml EGF (Life Technologies, Inc.) for 30 min in suspension or on* The costs of publication of this article were defrayed in part by the
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noncoated or poly-lysine-coated dishes. For stimulation by ECM (mouse
collagen type IV, human collagen type I, or human fibronectin), cells
were plated on ECM-coated dishes in the presence or absence of 5 nM
MSP or 50 mg/ml EGF for 30 min. After stimulation, cells were lysed in
lysis buffer (50 mM HEPES, pH 7.4, 150 mM NaCl, 10% glycerol, 1 mM
EDTA, 1 mM sodium orthovanadate, 10 mM sodium pyrophosphate, 100
mM NaF, 1% Triton X-100, 10 mg/ml leupeptin, 10 units/ml aprotinin, 1
mM phenylmethylsulfonyl fluoride). Insoluble material was removed by
centrifugation, and RON receptor was immunoprecipitated from super-
natants using mouse monoclonal anti-RON antibodies (clone ID2). RON
tyrosine phosphorylation was detected by Western blotting using anti-
phosphotyrosine antibodies (anti-PY, clone 4G10, Upstate Biotechnol-
ogy, Inc., Lake Placid, NY). Rabbit anti-RON antibodies (Santa Cruz
Biotechnology, Santa Cruz, CA) were used for detection of RON on the
membranes.
RON Kinase Assay in Vitro—RON was immunoprecipitated from cell
lysates by RON antibodies. Immunoprecipitates were washed twice in
HNTG buffer (50 mM HEPES, pH 7.4, 150 mM NaCl, 0.1% Triton X-100,
10% glycerol) and twice in kinase buffer (20 mM HEPES, pH 7.4, 10%
glycerol, 10 mM MgCl2, 10 mM MnCl2, 150 mM NaCl). To initiate kinase
reactions, 15 mCi of [g32P]ATP (3000 Ci/mmol, 10 mCi/ml) was added,
and immunoprecipitates were incubated for 30 min at room tempera-
ture in 15 ml total volume. The exogeneous substrate, myelin basic
protein (MBP), was added to the kinase reaction mixture at a concen-
tration of 0.5 mg/reaction tube. Reactions were stopped with 5 ml of 43
sample buffer. Phosphorylated RON or its substrate, MBP, were visu-
alized after SDS-PAGE by autoradiography.
Phosphorylation of RON by c-Src in Vitro—Pure constitutively active
c-Src enzyme (3 units/sample; Upstate Biotechnology, Inc.) was incu-
bated with immunoprecipitated RON and 15 mCi of [g32P]ATP (3000
Ci/mmol, 10 mCi/ml) in kinase buffer for 30 min at room temperature,
and incorporation of 32P into RON was detected by autoradiography
after SDS-PAGE.
Assay of Cell Accumulation in Tissue Culture—RE7 cells (MDCK
cells stably expressing the RON receptor, 1 3 104 cells/well) were plated
in triplicate into 96-well tissue culture plates, uncoated (control) or
coated with mouse collagen type IV, and incubated in the presence or
absence of 1 nM MSP in DMEM without FCS. Cell numbers were
measured after 48 h by adding 3-[4,5-dimethylthiazol-2-yl]-2,5-diphe-
nyltetrazolium bromide (MTT) into culture wells and measuring A570
2 h later. The number of cells was determined from an MTT calibration
curve for this cell line.
RESULTS AND DISCUSSION
In the present work, we investigated the effect of integrin-
dependent adhesion on the functional activity of RON and the
molecular mechanisms mediating this effect. Plating of RON-
expressing HEK 293 epithelial cells on a collagen-coated sub-
strate induced ligand-independent RON tyrosine phosphoryla-
tion (Fig. 1A, lane 3) and kinase activity (Fig. 1B, lane 3). The
Addition of MSP to collagen-adherent cells caused a higher
level of RON phosphorylation and kinase activity than either
MSP or collagen alone (Fig. 1, A and B). The time courses of
RON phosphorylation induced by these different stimuli were
comparable, with a plateau at about 30 min (data not shown).
RGD-containing peptide or anti-b1-integrin antibodies blocked
ECM-induced RON activation (data not shown), indicating that
the effect of ECM (collagen types I and IV, fibronectin) on RON
phosphorylation and activation is mediated by integrins. Sim-
ilar results were obtained with MDCK cells stably expressing
transfected RON and with the human HaCat keratinocyte cell
line that expresses endogenous RON (data not shown). In ad-
dition to the effect on RON phosphorylation and kinase activ-
ity, the combination of MSP and ECM maximized epithelial cell
numbers, measured after 48 h in culture (Table I). Effects of
ECM, alone or with growth factor, on receptor phosphorylation
or downstream mediators have been described for Met (25),
EGF (7, 8, 13–16), PDGF (7, 8, 16), fibroblast growth factor (8),
VEGFR-2 (17), and insulin (16) receptors in various cell types,
indicating that cell-ECM interactions frequently regulate
growth factor-RTK responses.
In thinking about a molecular mechanism mediating the
ECM effect on RON, we considered two possibilities, which are
not mutually exclusive. 1) Inasmuch as RON is associated with
b1 integrin (24), ECM-induced integrin aggregation could re-
sult in RON oligomerization, transphosphorylation, and in-
creased RON kinase activity; and (2) tyrosine kinases activated
by integrins might phosphorylate and activate RON.
Two tyrosine-specific cytoplasmic kinases, focal adhesion ki-
nase (FAK) and c-Src, can be activated in response to cell-ECM
FIG. 1. Stimulus-induced tyrosine phosphorylation and kinase
activity of RON transiently expressed in HEK 293 cells. Cells in
serum-free medium were stimulated in suspension with 5 nM MSP or
plated on mouse collagen IV (Col IV)-coated dishes in the presence of
MSP or medium alone for 30 min. Cells were then lysed, and RON was
immunoprecipitated from the lysates for detection of tyrosine phospho-
rylation or kinase activity. A, RON tyrosine phosphorylation was de-
tected by Western blotting with anti-phosphotyrosine (WB: PY) anti-
bodies. The level of RON phosphorylation was calculated by
densitometry of the phosphorylated RON bands on the blots and ex-
pressed as a percent of the RON phosphorylation level induced by the
combination of MSP and collagen IV. Bar graph data are means 6 S.E.
of three independent experiments. The upper blot shows results of a
representative experiment demonstrating the levels of RON phospho-
rylation. The lower blot, developed with anti-RON, is a control for the
amount of RON in precipitates. The two bands represent immature
(upper band) and mature RON (lower band). B, RON kinase activity
was assayed in vitro using [32P]ATP and MBP as substrates. The level
of RON kinase activity was calculated by densitometry of the phospho-
rylated MBP bands on the autoradiographs and expressed as a percent
of the MBP phosphorylation induced by the combination of MSP and
collagen IV. Bar graph data are means 6 S.E. of three independent
experiments. The autoradiograph shows results of one experiment dem-
onstrating incorporation of 32P into MBP.
TABLE I
Effect of collagen type IV on MSP-induced accumulation of RE7
(MDCK RON-expressing) cells
Cells (104/well) were distributed in triplicate in 96-well plates, un-
coated or coated with mouse collagen IV, and incubated with or without
1 nM MSP in DMEM without FCS. Cell numbers were measured 48 h
later by adding MTT to culture wells and measuring A570 2 h later. The
number of cells was determined from a standard calibration curve. The
means 6 S.E. for three independent experiments are shown in the
table.
Cell no. 3 1024
Uncoated wells 1.5 6 0.2
Uncoated wells 1 1 nM MSP 3.2 6 0.3
Collagen IV-coated wells 3.8 6 0.4
Collagen IV-coated wells 1 1 nM MSP 5.6 6 0.5
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adhesion (26). Cell adhesion to ECM induces integrin aggrega-
tion and activation of FAK, which is associated with b integrin.
The initial step in FAK activation is transphosphorylation of
Tyr397, after which c-Src can bind phosphorylated Tyr397 via its
SH2 domain (27). This interaction between FAK and c-Src
increases c-Src kinase activity. Activation of FAK and c-Src is
a key point in integrin-mediated signal transduction (26).
To study the role of FAK in integrin-mediated RON phos-
phorylation, we co-expressed transiently wild type RON with
the major autophosphorylation site (Y397F) FAK mutant in
HEK 293 cells. In cells expressing the Y397F FAK mutant, the
level of collagen-induced RON phosphorylation was about one-
half that of cells transfected with vector alone (Fig. 2A). The
fact that the FAK Y397F mutant decreased ECM-induced RON
phosphorylation suggested the involvement of c-Src, a down-
stream kinase, for which FAK-phosphorylated Tyr397 is a bind-
ing site (27).
To test for a role of c-Src in ECM-induced RON phosphoryl-
ation, we transfected HEK 293 cells with a dn kinase-inactive
c-Src construct. Collagen-induced RON phosphorylation (Fig.
2B) in these cells was reduced comparable with the Y397F FAK
mutant (Fig. 2A). These data were consistent with the postu-
lated ECM-integrin-FAK-c-Src pathway, suggesting that RON
is phosphorylated by activated c-Src.
We therefore determined the capacity of c-Src to phosphoryl-
ate RON in vitro by adding active purified c-Src enzyme to
RON immunoprecipitated from HEK 293 cells. These cells were
also transfected with the kinase-inactive c-Src construct, in
addition to RON, to prevent possible in vivo c-Src activity. RON
was immunoprecipitated from cells that were either unstimu-
lated or stimulated with MSP or collagen. Active c-Src in vitro
phosphorylated RON from collagen-stimulated cells but failed
to phosphorylate RON from unstimulated or MSP-stimulated
cells (Fig. 3). These results indicate that c-Src can phosphoryl-
ate RON but that sites become available for phosphorylation by
c-Src only on RON from cells stimulated with ECM. In contrast
to our findings, it has been reported that c-Src can phosphoryl-
ate nonstimulated or ligand-stimulated growth factor receptors
(28–30); these published results are with cultured adherent
cells, the integrins of which might be engaged by fibronectin
derived from cells or serum.
Fig. 3 also shows that although MSP alone does not make
RON a target for phosphorylation by c-Src, it enhances the
response to collagen. This apparent synergy between MSP and
collagen in making RON a target for c-Src might be the result
FIG. 2. FAK major autophosphorylation site Y397F mutant (A)
or dn c-Src (B) inhibits collagen IV-induced RON tyrosine phos-
phorylation in HEK 293 cells. HEK 293 cells transiently co-trans-
fected with RONwt plus FAK Y397F mutant (A) or with RONwt plus dn
c-Src (B) were stimulated with MSP, collagen IV, or both, as described
in the legend to Fig. 1. After stimulation, RON was immunoprecipitated
from cell lysates, and tyrosine phosphorylation was determined by
Western blotting with anti-PY antibodies (WB: PY) (A and B, upper
panels). The lower panels represent re-blotting with anti-RON antibod-
ies to estimate the amount of RON in precipitates. MOCK: empty
vector.
FIG. 3. C-Src kinase phosphorylates RON from ECM-stimu-
lated cells but not from unstimulated or MSP-stimulated cells.
A, HEK 293 cells transiently co-transfected with RONwt and dn c-Src
were stimulated with MSP, collagen IV (Col IV), or both, as described in
the legend to Fig. 1. After stimulation, RON was immunoprecipitated
from cell lysates and tested in vitro as a substrate for purified active
c-Src enzyme. RON phosphorylation was determined by incubation of
immunoprecipitated RON with [32P]ATP alone (upper panel) or in the
presence of active c-Src (3 units/sample) (lower panel). 32P incorporation
was detected by SDS-PAGE and autoradiography. B, c-Src-induced
RON phosphorylation was calculated by densitometry of the phospho-
rylated RON bands and expressed as a ratio of 32P incorporation into
RON in the presence and absence of c-Src. Data are means 6 S.E. for
five independent experiments. p values are shown above the bars: *, p ,
0.05, differences between the cells stimulated with collagen or collagen
plus MSP (MSP 1 Col IV) versus nonstimulated control (Contr) or
MSP-stimulated cells; **, p , 0.05, difference between the cells stimu-
lated with collagen 1 MSP versus collagen-stimulated cells.
FIG. 4. Collagen-induced EFGR tyrosine phosphorylation de-
pends on EFGR (A) and c-Src (B) kinase activities. MDCK cells
expressing endogenous EGFR were stimulated in suspension with 50
ng/ml EGF or plated on mouse collagen IV (Col IV)-coated dishes in the
presence of EGF or in medium alone (control (Contr)) for 30 min. For
inhibition of EGFR activity, 250 nM tyrphostin AG1478 was added at
the beginning of cell stimulation. For detection of c-Src effect on EGFR
phosphorylation, MDCK cells were co-transfected with empty vector
(MOCK) and MACS4 selection vector or with dn c-Src cDNA and
MACS4 vector; after selection, positively transfected cells were used.
After stimulation, EGFR was immunoprecipitated (IP: EGFR) from cell
lysates and used for the detection of tyrosine phosphorylation by West-
ern blotting with anti-PY (WB: PY) antibodies. Re-probing of the mem-
brane with anti-EGFR antibodies provided an estimate of the amount of
EGFR in precipitates. The numbers at the bottom of the figure are
densitometric data for phosphorylated EFGR bands expressed as a
percent of EGFR phosphorylation levels induced by the combination of
EGF and collagen IV.
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of increased RON kinase activity (Fig. 1B, last bar).
How does stimulation by ECM make RON a target for c-Src?
A clue was provided by the fact that expression of either Y397F
FAK or kinase-inactive c-Src only partially decreased ECM-
induced RON phosphorylation (Figs. 2 and 3), suggesting that
a kinase distinct from FAK and c-Src is involved in ECM-
induced RON phosphorylation. We considered the possibility
that RON itself might play that role. To test whether RON
kinase activity was required for ECM-mediated RON phospho-
rylation, we expressed a kinase-dead RON (RONkd) construct
in HEK 293 cells. Stimulation of RONkd-293 cells with MSP or
collagen did not cause RON phosphorylation (data not shown).
Moreover, active purified c-Src in vitro did not phosphorylate
RONkd immunoprecipitated from collagen- or MSP-stimulated
cells (data not shown), which is additional evidence that non-
phosphorylated RON is not a substrate for c-Src. Thus, RON
kinase activity is essential for ECM-mediated effects on RON.
This finding correlates with observations that PDGF (7) and
EGF (13) receptor kinase activity is necessary for ECM-induced
receptor phosphorylation.
Our results suggest that ECM-induced RON phosporylation
and activation occur in two steps. Step 1: because RON is
associated with b1 integrin (24), ECM-induced integrin aggre-
gation can lead to RON oligomerization and transphosphoryl-
ation, which causes an increase in RON kinase activity above
the basal level that initiates the autophosphorylation. Step 2:
RON molecules phosphorylated in step 1 are a target for c-Src
activated via the ECM-integrin-FAK pathway, which results in
the phosphorylation of additional tyrosines on RON. Data con-
sistent with step 1 are the requirement for RON kinase activity
for the ECM effect (no ECM effect on cells with RONkd) and
ECM-induced RON phosphorylation above unstimulated levels
in cells with step 2 blocked by kinase-inactive c-Src (Fig. 3).
Data consistent with step 2 are prevention of the additional
increment of ECM-induced phosphorylation in cells with ki-
nase-inactive c-Src (Fig. 3), and phosphorylation in vitro by
active c-Src of RON from ECM-adherent cells but not from
unstimulated cells.
We also found that adhesion to ECM by epithelial cells
expressing endogenous EGFR caused ligand-independent
EGFR tyrosine phosphorylation as well as increased EGF-de-
pendent tyrosine phosphorylation (Fig. 4A). In agreement with
our data for RON, ECM-mediated phosphorylation of the
EGFR requires kinase activity of both the EGFR itself and
c-Src. Inhibition of EGFR kinase activity by tyrphostin blocked
both EGF- and ECM-induced EGFR phosphorylation (Fig. 4A).
In contrast, inhibition of endogeneous c-Src kinase activity by
overexpression of kinase-inactive c-Src had no effect on EGF-
induced phosphorylation, but it prevented the collagen-medi-
ated increment (Fig. 4B). Thus, it appears that ECM-induced
EGFR phosphorylation occurs via the pathway outlined above
for RON, where EGFR catalytic activity and autophosphoryla-
tion are essential for c-Src to phosphorylate additional ty-
rosines on EGFR. Potentiation by c-Src of the mitogenic and
tumorigenic capacity of EGFR is mediated by phosphorylation
of additional tyrosines in EGFR by c-Src, when c-Src interacts
with phosphorylated EGFR (29). The fact that receptor phos-
phorylation induced by ECM-dependent adhesion occurs via
similar pathways for both RON and EGFR, which belong to
different growth factor receptor kinase families, suggests that
this is a common pathway that integrins may use for regulation
of growth factor RTK activity.
The nature of this regulation is a subject for further inves-
tigation. The fact that c-Src can phosphorylate RON from cells
stimulated by ECM, but not by MSP (Fig. 3B), is evidence that
the pattern of RON tyrosine phosphorylation induced by ECM
is distinct from that induced by MSP. There are 14 tyrosines in
the cytoplasmic domain of RON. The similarity among the
columns of Fig. 1, A and B, suggests that incremental increases
in phosphorylation of some of these tyrosines may correlate
with increments in RON kinase activity. It is also possible that
ECM or MSP stimulation results in phosphorylation of differ-
ent tyrosines, which could be unique docking sites for particu-
lar downstream mediators. This could result in different cellu-
lar responses, depending on whether RON was stimulated by
ECM or MSP. An example is the fact that epithelial cells
cultured in serum-free medium in collagen-coated dishes be-
come apoptotic, despite stimulation of RON by ECM adherence;
and yet stimulation of RON in the presence of MSP in these
cultures prevents the apoptosis (31). Our next step in this
investigation will therefore be to determine whether stimula-
tion by ECM and MSP results in phosphorylation of different
tyrosines in the RON cytoplasmic domain.
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